Clinical trial · Observational
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
NCT05624736CI-TRIAL-00062309unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Astrocytoma | Astrocytoma | CURATED_BROADER | 0.80 |
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
| Oligodendroglioma | Oligodendroglioma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| multi-parametric magnetic resonance imaging scan | Diagnostic Test | — | UNRESOLVED |
| Pathology examination | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Glioblastoma Group
- description
- Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
- interventionNames
- Diagnostic Test: multi-parametric magnetic resonance imaging scan
- Diagnostic Test: Pathology examination
- label
- Astrocytoma Group
- description
- Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
- interventionNames
- Diagnostic Test: multi-parametric magnetic resonance imaging scan
- Diagnostic Test: Pathology examination
- label
- Oligodendroglioma Group
- description
- Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma. 2. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences 3. No pre-surgery anti-tumor therapy Exclusion Criteria: 1. Poor image quality 2. Failed image preprocessing 3. Unavailable pathology data
References
Publications (0)
Data not yet available
No reference posted for this study.